Overdose deaths declined for 15 consecutive months starting in 2023
Using data from the National Center for Health Statistics and the Census Bureau, the analysis of drug overdose death rates was conducted from January 2015 to October 2024. Over 800,000 United States residents — 68 percent of them male with a median age of 42 — died of a drug overdose during the study period.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
United States Smart Pills Market Research and Company Analysis Report 2025-2033 Featuring Check-Cap, General Electric, Fujifilm, Koninklijke Philips, Medtronic, Olympus, Novartis, Otsuka
The United States Smart Pills Market is set to grow significantly, reaching US$ 4.13 billion by 2033, up from US$ 1.53 billion in 2024, with a CAGR of 11.66% from 2025 to 2033. Driving forces include rising demand for minimally invasive diagnostics, a surge in gastrointestinal disorders, an aging population, and advancements in wireless capsule technology. As telemedicine integrates smart pills, enhanced patient care and monitoring are expected. However, challenges like high technology costs and regulatory hurdles remain. Key players in the market include Check-Cap Ltd., General Electric, and Medtronic. U.S. Smart Pills Market Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "United States Smart Pills Market - Drug Delivery Innovation & Forecast 2025-2033" report has been added to States Smart Pills Market is expected to reach US$ 4.13 billion by 2033 from US$ 1.53 billion in 2024, with a CAGR of 11.66% from 2025 to 2033 Rising demand for minimally invasive diagnostics, an increase in gastrointestinal disorders, an aging population, improvements in wireless capsule technology, rising healthcare costs, and significant R&D investments from pharmaceutical and medical device companies are some of the major factors propelling the U.S. smart pill market. Smart pills, sometimes referred to as digital pills or ingestible sensors, are cutting-edge medications with microscopic electronic parts that allow for data collecting and remote monitoring. Patients often swallow these pills, which include transmitters, microchips, and sensors. After entering the body, they interact with biological fluids and communicate to external devices in real time information regarding a patient's physiological responses, medication adherence, and health indicators. This information is used by researchers and healthcare professionals to improve medication development, optimize treatment regimens, and improve patient care. By improving monitoring and data collection capabilities, smart tablets may have advantages in clinical trials, chronic illness management, and personalized treatment.A number of important factors are driving the growth of the smart pill industry in the United States. The use of smart pill technologies is being aided by the growing need for less invasive diagnostic techniques, particularly in conditions pertaining to the gastrointestinal and colon. The demand for better diagnostics is further increased by the aging population, which is more susceptible to chronic illnesses. Smart pills are now more capable and dependable thanks to technological developments in wireless connection, sensors, and micro-cameras. Their acceptance is aided by improving infrastructure and rising healthcare costs. Furthermore, the pharmaceutical and medical device industries' significant investments in R&D are spurring innovation and broadening the range of Drivers for the United States Smart Pills Market Rising Prevalence of Chronic DiseasesOne major factor propelling the growth of the smart pill market in the United States is the increasing incidence of chronic illnesses. Novel, non-invasive diagnostic approaches are needed for diseases such kidney disease, diabetes, and gastrointestinal disorders. As of February 2022, 92,000 people were waiting for kidney transplants, and an estimated 37 million Americans suffer from kidney disease, according to the American Kidney Fund. Furthermore, according to the American Cancer Society, there will likely be 79,000 new cases of kidney cancer detected in 2022, with men having a higher lifetime risk (2.02%) than women (1.03%). The need for sophisticated monitoring and diagnostic technologies, such smart pills, which facilitate early detection, ongoing health monitoring, and real-time data collection, is increasing as a result of these chronic illnesses. This tendency is propelling the use of smart pills and bolstering the market's expansion in the US, along with rising healthcare awareness and the need for minimally invasive AdvancementsThe market for smart pills in the United States is expanding due in large part to technological improvements. Real-time patient health monitoring is now possible thanks to advancements in wireless connection, downsizing, and sensor integration that have greatly improved the functionality of smart pills. These developments improve the ability of smart tablets to identify and treat diseases like cancer, chronic illnesses, and gastrointestinal with TelemedicineOne of the key growth drivers for the US healthcare industry is the combination of smart pills and telemedicine. These cutting-edge ingestible gadgets make it possible to track patients' health parameters in real time, including physiological reactions, medication compliance, and gastrointestinal disorders. Smart pills improve patient outcomes by enabling prompt interventions and individualized treatment programs by sending this data to healthcare practitioners. The COVID-19 pandemic hastened the uptake of telemedicine and made it easier to implement smart pills for remote patient monitoring. This collaboration promotes the transition to patient-centric healthcare models that place a higher priority on convenience and ongoing monitoring, while also enhancing access to care, particularly in underprivileged areas. The use of smart pills to provide effective, remote healthcare is anticipated to increase as telemedicine develops, which will increase consumer in the United States Smart Pills Market High Cost of TechnologyThe market for smart pills in the United States is significantly hampered by the high cost of technology. Smart pills are costly because they require sophisticated technology to be developed, manufactured, and integrated, including wireless connection, sensors, and downsizing. Due to the high cost, access may be restricted, especially for patients from lower-income groups or those without sufficient insurance coverage. The initial expenditures of equipment and training may also deter healthcare practitioners from implementing smart pill technology. Unless price improves, this could impede the broad acceptance and accessibility of smart pills, hence reducing their market ApprovalFor the smart pill market in the United States, regulatory approval is a major obstacle. Approval procedures for smart pills can be drawn out and complicated due to the FDA and other regulatory agencies' strict safety and effectiveness requirements. Strict adherence to guidelines, data validation, and comprehensive clinical trials are necessary for this. Market expansion and the marketing of new products might be slowed down by approval delays. Furthermore, the constantly changing landscape of smart pill technology frequently creates regulatory uncertainty because the special characteristics of these cutting-edge medical devices may not be adequately addressed by current frameworks, making the licensing process more Developments in United States Smart Pills Industry In Jan 2025, The FDA has approved CapsoVision, Inc. (US) to use CapsoCam Plus in pediatric patients two years of age and up. A non-invasive, comfortable diagnostic approach that reduces the stress usually associated with standard endoscopic procedures, this milestone enables youngsters to benefit from the simplicity and accuracy of capsule endoscopy. In Jan 2024, The FDA approved the expanded indications for AnX Robotics' (US) NaviCam Small Bowel Video Capsule Endoscopy (SB) for adults and children ages 2 and up. This significant accomplishment solidifies NaviCam SB as the most cutting-edge technology in small bowel video capsule endoscopy, as does the FDA's recent approval of ProScan, the ground-breaking AI-assisted reading tool for VCE. Key Players Analysis: Company Overview, Key Persons, Recent Development & Strategies, Sales Analysis Check-Cap Ltd. General Electric Company Fujifilm Koninklijke Philips N.V. Medtronic plc. Olympus Corporation Novartis AG Otsuka Holdings Co., Ltd. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $1.53 Billion Forecasted Market Value (USD) by 2033 $4.13 Billion Compound Annual Growth Rate 11.6% Regions Covered United States Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. United States Smart Pills Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Application6.2 By Target Area6.3 By End Users7. Application7.1 Capsule Endoscopy7.2 Patient Monitoring7.3 Drug Delivery8. Target Area8.1 Esophagus8.2 Small Intestine8.3 Large Intestine8.4 Stomach9. End Users9.1 Diagnostic Centers9.2 Hospitals9.3 Research Institutes9.4 Others10. Porter's Five Forces Analysis10.1 Bargaining Power of Buyers10.2 Bargaining Power of Suppliers10.3 Degree of Rivalry10.4 Threat of New Entrants10.5 Threat of Substitutes11. SWOT Analysis11.1 Strength11.2 Weakness11.3 Opportunity11.4 Threat12. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Smart Pills Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Scientists raise red flag over effects of microscopic threat to vital organs: 'A potential health risk'
Scientists raise red flag over effects of microscopic threat to vital organs: 'A potential health risk' A new study on mice has highlighted the damage that ingested microplastics can cause to different organs. What's happening? Researchers assessed the toxicity of polystyrene microplastics to the gut and mammary glands in subject mice, according to the study, published in the journal Science of Food. The scientists found that the tiny plastic particles accumulated in various tissues, causing significant harm to the gut and mammary glands. Specifically, they found that microplastics could "disrupt the intestinal barrier" and lead to inflammation of the colon and an imbalance of the gut microbiome. They also observed that microplastics can accumulate in mammary tissue, causing inflammatory damage there, among other effects. "These findings indicate that ingestion of microplastics poses a potential health risk," the authors stated. "Further control of microplastics contamination in food is needed to promote public health and wellness." Why are microplastics concerning? The study added to a growing understanding and body of research about the health impacts of microplastics. For instance, a previous experiment on pigs discovered that microplastic exposure can trigger an inflammatory response in the enteric nervous system, which affects functions including immune responses. The effects of microplastics on human health are still being explored. But other studies have linked microplastic exposure to health problems such as cancer, dementia, and impaired blood flow in the brain. What's being done about microplastics? Though microplastics pollute soil, water, food, and air, scientists are discovering new ways to remove them from our environment. For instance, one team found a way to get them out of soil by using a type of processed farm waste. You can help reduce the amount of microplastics entering the environment, and reduce your own exposure, by opting for plastic-free alternatives to everyday products. Choose reusable bottles and containers instead of single-use varieties, for instance. Do you worry about having toxic forever chemicals in your home? Majorly Sometimes Not really I don't know enough about them Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
Medscape
3 hours ago
- Medscape
Starting a Family as a Physician: Delays, Struggles Abound
A 2023 survey of 1056 women physicians revealed a troubling pattern: Despite having comprehensive medical knowledge of age-related fertility decline, 3 in 4 delayed childbearing and more than 1 in 3 experienced infertility. The numbers, published in JAMA Network Open , tell a stark story. Physicians start families at a median age of 32 years vs 27 years among nonphysicians, according to research in JAMA Internal Medicine . This delay has real consequences — female physicians are two times more likely to experience infertility than women of reproductive age in the general population. The problem isn't lack of knowledge. It's that medical training timelines directly collide with prime reproductive years, creating impossible choices that affect not just individual physicians but also patient care and healthcare workforce stability. When Training Schedules Clash With Biology Medical education stretches well into the third decade of life. By the time physicians complete residency and fellowship training, many are in their early to mid-thirties — precisely when fertility begins its steepest decline. Tomer Singer, MD The daily realities are unforgiving. Tomer Singer, MD, board-certified in reproductive endocrinology and infertility and obstetrics and gynecology at Northwell Health in New York City, witnesses this struggle regularly. 'I've cared for residents who came in for monitoring appointments at 6:00 AM so they could make it to rounds by 7:00,' Singer said. 'I've helped coordinate egg retrievals around call schedules and operating room time.' The pressure to delay childbearing comes from multiple directions. Susan B. Hudson, MD, board-certified in reproductive endocrinology and infertility and obstetrics and gynecology at the Texas Fertility Center in Corpus Christi, Texas, experienced this firsthand during her own training. 'Residency is very time-consuming, and there's really not a lot of time for maternity leave,' Hudson said. 'If you're gone, you have to make up that time in the end. A major consideration was my colleagues and the other residents in the program because they relied on me.' This creates a medical paradox. Physicians understand better than anyone that fertility declines significantly after 32, yet they face institutional and financial pressures that make family planning during their prime reproductive years nearly impossible. Educational debt and minimal trainee salaries compound the problem, limiting access to fertility preservation options just when they're most needed. The Personal and Professional Toll The consequences extend far beyond statistics. Female physicians experience infertility two times more than women in the general population, and the JAMA Network Open survey found that nearly half the physician mothers reported passing up career advancement opportunities to accommodate family building. The physical demands of training don't pause for pregnancy complications. Hudson recalls a particularly difficult experience. 'At one point, I did end up spending the night at the hospital in labor and delivery for monitoring. I was discharged the next morning, and I was expected to go straight to clinic to see patients, so I did.' Susan B. Hudson, MD Professional milestones often collide with new parenthood in ways that would be unthinkable in other careers. 'I was going through the process of taking my ob/gyn oral boards 4 weeks after giving birth,' Hudson said. 'I had a newborn, and I was breastfeeding; this was back in 2007 when there really weren't a lot of designated spaces to pump (breast milk).' Sometimes, institutional policies create additional barriers. When Hudson decided to pursue in vitro fertilization for her third child, she encountered an unexpected obstacle at the practice where she worked. 'They had a policy where employees were not permitted to seek fertility care with the clinic,' she said. 'We elected to travel for treatment so we could continue to grow our family.' Singer has witnessed the emotional impact on colleagues. 'I've supported colleagues who suffered miscarriages in between cases or during long hospital shifts,' he said. 'They continued working while carrying the weight of that loss, often without time to grieve or even talk about it.' These individual struggles contribute to broader systemic problems. When physicians delay or forgo family building, it perpetuates gender disparities in medical leadership and creates retention challenges in demanding specialties. Emerging Solutions, But Gaps Remain Some forward-thinking institutions are starting to address these challenges. Boston IVF, Reproductive Medicine Institute, and Shady Grove Fertility have introduced discounted egg-freezing programs specifically designed for US residents and fellows, with eligibility timelines that recognize the unique constraints of medical training. Professional boards are also adapting. The American Board of Family Medicine now allows up to 12 weeks of family leave per year without requiring training extension, a significant increase from the previous 30-day limit. The policy permits up to 20 weeks of total leave across a 3-year residency and includes provisions for hardship waivers when medical conditions arise. But these advances remain exceptions. Most graduate medical education benefit plans still don't cover elective fertility preservation, leaving the financial burden on physician families already struggling with educational debt. Meanwhile, some institutions maintain counterproductive policies — like Hudson's experience with a clinic that prohibited employees from receiving fertility care at their own workplace, forcing her to travel for treatment. The support landscape varies dramatically. Some training programs have developed comprehensive policies that include modified duty assignments, robust lactation support, and extended parental leave. Others maintain rigid schedules that offer little flexibility for family planning needs. Mark P. Leondires, MD For some physicians, the challenges go beyond timing. Mark P. Leondires, MD, board-certified in reproductive endocrinology and founder and medical director of Illume Fertility in Norwalk, Connecticut, navigated his own complex family-building journey. 'We pursued surrogacy with the help of egg donation, an incredible but highly complex journey, especially for LGBTQ+ parents,' Leondires said. Professional organizations have begun to take notice. The American Medical Association and specialty societies have developed policy statements supporting family-friendly practices in medical training, but implementation remains inconsistent across institutions. What's missing is comprehensive data on what works. Systematic evaluation of existing programs and their impact on physician satisfaction and career outcomes would help guide future policy development. Rethinking Medical Education The solution requires fundamental changes in how medical education approaches work-life integration. Flexible residency pathways could accommodate extended training timelines for those pursuing fertility treatments or early parenthood. Technology-enabled learning offers opportunities for remote participation when in-person attendance isn't feasible. Standardized policies across graduate medical education programs would ensure that support doesn't depend on geography. Essential components should include fertility preservation coverage, meaningful parental leave, comprehensive lactation support, and modified duty assignments when medically necessary. The cultural shift may be the most important change. As Singer put it: 'Medicine asks a lot of those who choose this path. But it shouldn't ask us to give up the possibility of parenthood.' Research priorities should include long-term studies comparing career outcomes between physicians who received family-friendly support and those who didn't. Economic analyses could help institutions understand the return on investment in terms of physician retention and satisfaction. Partnerships between medical institutions, fertility clinics, and professional organizations offer scalable solutions. The success of targeted programs at major fertility centers demonstrates that industry-wide initiatives are feasible.
